(AOF) – Valbiotis, a biotech company specializing in the prevention and fight against metabolic and cardiovascular diseases, announces the last visit of the last patient included in the Phase II/III Reverse-IT study on the active substance Totum 63. Conducted on 600 untreated prediabetic and type 2 diabetic patients (early stage), this international, multicenter, randomized and placebo-controlled study should confirm the efficacy of the product on alterations in glucose metabolism. The first results will be communicated before the end of the first half of 2023.
Totum 63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. It has been developed to meet a large unmet need: to act on metabolic alterations from the early stages of type 2 diabetes. , particularly that of prediabetes. Prediabetes today concerns nearly 900 million people in the world, including 128 million in the United States and in the 5 main European countries, for which no non-drug health product has yet solid proof of effectiveness.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.